Citations

Clear

371 citation(s) found for "Cho, B".

Tissue valves are preferable for patients with end-stage renal disease: an aggregate meta-analysis
Altarabsheh, Salah E. , Obeidat, Yaqthan M., Erwin, Patricia J., Rababa’h, Abeer , Sarabhu, Nagaraju, Navale, Suparna , Lamba, Harveen K. , Markowitz, Alan , Park, Soon J., Dunlay, Shannon M. , Deo, Salil V. , Cho, Yang Hyun , Altarabsheh, Salah

Mayo Clinic

Journal of Cardiac Surgery | July 8, 2016 | Volume: 31 | Issue: 8 | Pages: 507-514

10.1111/jocs.12805 | PMID 27389823 Get It

“This lifetime commitment”: Public conceptions of disability and noninvasive prenatal genetic screening
Steinbach, Rosemary J. , Allyse, Megan , Michie, Marsha , Liu, Emily Y., Cho, Mildred K. , Allyse, Megan A

Mayo Clinic

American Journal of Medical Genetics Part A | November 14, 2015 | Volume: 170 | Issue: 2 | Pages: 363-374

10.1002/ajmg.a.37459 | PMID 26566970 Get It

Recently, new noninvasive prenatal genetic screening technologies for Down syndrome and other genetic conditions have become commercially available. Unique characteristics of these screening tests have reignited long‐standing concerns about prenatal testing for intellectual and developmental disabilities. We conducted a web‐based survey of a sample of the US public to examine how attitudes towards disability inform views of prenatal testing in the context of these rapidly advancing prenatal genetic screening technologies. Regardless of opinion toward disability, the majority of respondents supported both the availability of screening and the decision to continue a pregnancy positive for aneuploidy. Individuals rationalized their support with various conceptions of disability; complications of the expressivist argument and other concerns from the disability literature were manifested in many responses analyzed. © 2015 Wiley Periodicals, Inc.
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PRECiSE 3 study
Sandborn, William J. , Melmed, Gil , Loftus, Edward V. , Cho, J.‐H. , Abraham, Bincy , Lichtenstein, Gary R. , Lee, S. D., Randall, Charles , Regueiro, Miguel, Spearman, Marshall, Kosutic, Gordana, Pierre‐Louis, Bosny, Coarse, Jason, McGovern, Dermot , Choi, J. M., Gutiérrez, Ana , Schwartz, David A. , Siegel, Corey A , Schreiber, Stefan , Loftus, Edward V , Melmed, Gil Y

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 1, 2015 | Volume: 42 | Issue: 3 | Pages: 330-342

10.1111/apt.13251 | PMID 26031921 Get It

SUMMARYBackgroundClinical factors were previously identified as predictors of short‐term treatment efficacy in Crohn's disease (CD). The PRECiSE 3 (P3) 7‐year trial provides an opportunity to study predictors of short‐ and long‐term clinical remission among CD patients treated with certolizumab pegol (CZP).AimTo identify factors that influence long‐term remission of CD with CZP treatment.MethodsPatients who had completed placebo‐controlled studies (PRECiSE 1/PRECiSE 2, P1/P2) enrolled in P3 and received open‐label CZP 400 mg every 4 weeks up to 7 years. Baseline predictors included, but were not limited to, smoking status, disease duration, prior inflammatory bowel disease (IBD) surgery, Harvey–Bradshaw Index (HBI), albumin, haematocrit and CZP exposure; association with time to initial remission (HBI ≤4) was tested for patients who received CZP in P1/P2; time to loss of remission/frequency of maintenance of remission was also tested. Univariate analyses and multivariate Cox or logistic regression models were used.ResultsPredictors for initial remission (N = 377) included age, haematocrit, prior IBD surgery and entry HBI (P < 0.05 for all). Predictors for loss of remission (N = 437) included HBI, serum albumin concentration, haematocrit, smoking status and exposure. Predictors of maintenance of remission (N = 437) included haematocrit, IBD surgery, HBI, disease duration, serum albumin concentration and exposure. Significant predictors were confirmed with stepwise multivariate regression models.ConclusionsThese analyses identified several influential parameters for short‐and long‐term remission of Crohn's disease with certolizumab pegol treatment. The data yield valuable hypotheses regarding factors that influence certolizumab pegol treatment. More investigation is needed.(ClinicalTrials.gov identifier NCT00552058).
iTagPlot: an accurate computation and interactive drawing tool for tag density plot
Ezenwoye, Onyeka, Cho, Hwan-Gue, Robertson, Keith D. , Choi, Jeong‐Hyeon , Kim, Sunghwan , Cho, Hwan-Gue, Robertson, Keith D

Mayo Clinic

Bioinformatics | March 20, 2015 | Volume: 31 | Issue: 14 | Pages: 2384-2387

10.1093/bioinformatics/btv166 | PMID 25792550 Get It

Abstract Motivation: Tag density plots are very important to intuitively reveal biological phenomena from capture-based sequencing data by visualizing the normalized read depth in a region. Results: We have developed iTagPlot to compute tag density across functional features in parallel using multicores and a grid engine and to interactively explore it in a graphical user interface. It allows us to stratify features by defining groups based on biological function and measurement, summary statistics and unsupervised clustering. Availability and implementation: http://sourceforge.net/projects/itagplot/. Contact: jechoi@gru.edu and jeochoi@gmail.com Supplementary information: Supplementary data are available at Bioinformatics online.
Building a Central Repository for Research Ethics Consultation Data: A Proposal for a Standard Data Collection Tool
Cho, Mildred K. , Anderson, Nick, Barnard, David , Boyle, Mary B., Capron, Alexander Morgan , Dorfman, Elizabeth, Havard, Kathryn, Reider, Carson, Sadler, John Z. , Sharp, Richard R. , Wilfond, Benjamin S. , McCormick, Jennifer B, Taylor, Holly A. , McCormick, Jennifer Blair , Anderson, Nick, Schwartz, Peter H. , Danis, Marion , Sharp, Richard R

Mayo Clinic

Clinical and Translational Science | March 10, 2015 | Volume: 8 | Issue: 4 | Pages: 376-387

10.1111/cts.12268 | PMID 25758372 Get It

AbstractClinical research ethics consultation services have been established across academic health centers over the past decade. This paper presents the results of collaboration within the CTSA consortium to develop a standard approach to the collection of research ethics consultation information to serve as a foundation for quality improvement, education, and research efforts. This approach includes categorizing and documenting descriptive information about the requestor, research project, the ethical question, the consult process, and describing the basic structure for a consult note. This paper also explores challenges in determining how to share some of this information between collaborating institutions related to concerns about confidentially, data quality, and informatics. While there is much still to be learned to improve the process of clinical research ethics consultation, these tools can advance these efforts, which, in turn, can facilitate the ethical conduct of research.
SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer
Budd, G. Thomas , Hobday, Timothy J. , Stewart, James A. , Salim, Muhammad , Cho, Jonathan K., Rinn, Kristine , Albain, Kathy S. , Chew, Helen K. , Burton, Gary V., Moore, Timothy D., Srkalović, Gordan , Flaherty, Lawrence E. , Livingston, Robert B., Lew, Danika L., Budd, George T, Rinn, Kristine J, McGregor, Bradley A. , Barlow, William E. , Moore, Halle C. F. , Isaacs, Claudine , Gralow, Julie R. , Hortobágyi, Gabriel N.

Mayo Clinic

Journal of Clinical Oncology | November 25, 2014 | Volume: 33 | Issue: 1 | Pages: 58-64

10.1200/jco.2014.56.3296 | PMID 25422488 Get It

Purpose To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients and Methods A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with node-positive or high-risk node-negative early-stage breast cancer. With 3,250 patients, a disease-free survival (DFS) hazard ratio of 0.82 for each randomization could be detected with 90% power with two-sided α = .05. Overall survival (OS) was a secondary outcome. Results Interim analyses crossed the futility boundaries for demonstrating superiority of both once-per-week regimens and once-every-2-weeks regimens. After a median follow-up of 6 years, a significant interaction developed between the two randomization factors (DFS P = .024; OS P = .010) in the 2,716 patients randomly assigned in the original design, which precluded interpretation of the two factors separately. Comparing all four arms showed a significant difference in OS (P = .040) but not in DFS (P = .11), with all treatments given once every 2 weeks associated with the highest OS. This difference in OS seemed confined to patients with hormone receptor–negative/human epidermal growth factor receptor 2 (HER2) –negative tumors (P = .067), with no differences seen with hormone receptor–positive/HER2-negative (P = .90) or HER2-positive tumors (P = .40). Conclusion Patients achieved a similar DFS with any of these regimens. Subset analysis suggests the hypothesis that once-every-2-weeks dosing may be best for patients with hormone receptor–negative/HER2-negative tumors.
Prevalence and risk factors for dysphagia: a USA community study
Cho, Seyoung , Choung, Rok Seon , Saito, Y. A., Schleck, C. D., Zinsmeister, A. R., Locke, G. Richard, Talley, N. J., Saito, Y. A., Choung, Rok Seon

Mayo Clinic

Neurogastroenterology & Motility | November 7, 2014 | Volume: 27 | Issue: 2 | Pages: 212-219

10.1111/nmo.12467 | PMID 25376877 Get It

AbstractBackgroundDysphagia is considered an alarm symptom but detailed population‐based data on dysphagia are lacking. We aimed to estimate in a representative USA Caucasian population, the prevalence of dysphagia and potential risk factors.MethodsA modified version of the previously validated Bowel Disease Questionnaire was mailed to a population‐based cohort (n = 7640) of Olmsted County, MN. Dysphagia was measured by one validated question ‘In the last year, how often have you had difficulty swallowing (a feeling that food sticks in your throat or chest)?’ The medical records were reviewed for organic causes of dysphagia. The associations of reported frequency of dysphagia with potential risk factors were assessed using logistic regression models.Key ResultsThe sex‐specific, age‐adjusted (US White 2000) prevalence for dysphagia experienced at least weekly was 3.0% (95% CI: 2.2, 3.7) in females and 3.0% (95% CI: 2.0, 4.0) in males. Those with frequent heartburn (OR = 5.9 [4.0, 8.6]) and acid regurgitation (OR = 10.6 [6.8, 16.6]) were significantly more likely to report frequent dysphagia. Proton pump inhibitor (PPI) use was significantly associated with frequent (3.1, 95% CI 2.2, 4.4) and infrequent dysphagia (1.5, 955 CI 1.3, 1.8). Gastro‐esophageal reflux disease (GERD) was the most common diagnosis in those reporting dysphagia on the medical record; other organic explanations were rare and only found in the frequent dysphagia group.Conclusions & InferencesFrequent dysphagia is not rare in the community (3%), occurs in both women and men across all adult age groups, and is most likely to indicate underlying GERD.
Melittin Inhibits TGF-β-Induced Pro-Fibrotic Gene Expression Through the Suppression of the TGFβRII-Smad, ERK1/2 and JNK-Mediated Signaling Pathway
Park, Suhyun , Cho, Hyun-Ji , Shin, Jae-Moon, Kang, Jeong Han , Park, Kwan‐Kyu , Choe, Jung‐Yoon , Park, Yoon-Yub , Han, Sang‐Mi , Moon, Sung‐Kwon , Chang, Young‐Chae , Jeong, Yun‐Jeong , Bae, Young‐Seuk , Kim, Wun‐Jae , Choi, Yung Hyun

Mayo Clinic

The American Journal of Chinese Medicine | September 2, 2014 | Volume: 42 | Issue: 05 | Pages: 1139-1152

10.1142/s0192415x14500712 | PMID 25178280 Get It

Renal fibrosis is characterized by the excessive accumulation of extracellular matrix (ECM) proteins such as type I collagen, fibronectin, and by the increased expression of PAI-1. This study evaluated the anti-fibrotic effect of bee venom and its major compounds (melittin and apamin) on TGF-β-induced pro-fibrotic gene expression. Bee venom and melittin significantly suppressed type I collagen, fibronectin, and PAI-1 protein expression in the TGF-β-treated kidney fibroblast. However, apamin only inhibited the expression of fibronectin and type I collagen. These results indicated that the inhibitory effects of bee venom on TGF-β-induced pro-fibrotic gene expression are caused by melittin. Moreover, we attempted to elucidate mechanisms underlying the anti-fibrotic effect of melittin. Melittin dramatically inhibited the phosphorylation of TGFβRII and Smad2/3. Also, melittin inhibited the phosphorylation of ERK1/2 and JNK, but not the phosphorylation of PI3K, Akt, and p38. These results suggested that melittin inhibits TGF-β-induced pro-fibrotic genes expression through the suppression of TGFβR-Smad2/3, ERK1/2, and JNK phosphorylation, and melittin can be used as a clinical drug for the treatment of fibrosis associated with renal diseases.
Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer
Fackler, Mary Jo , Lopez‐Bujanda, Zoila A. , Umbricht, Christopher B. , Teo, Wei Wen , Cho, Soonweng , Zhang, Zhe , Visvanathan, Kala , Jeter, Stacie C., Argani, Pedram, Lyman, Jaclyn P. , Brot, Marina De , McGuire, Kandace P. , King, Tari A. , Cope, Leslie , Wolff, Antonio C. , Wang, Chenguang , Ingle, James N. , Boughey, Judy C. , Carey, Lisa A. , Sukumar, Saraswati , Wolff, Antonio C , Visvanathan, Kala , Lopez-Bujanda, Zoila A

Mayo Clinic

Cancer Research | April 15, 2014 | Volume: 74 | Issue: 8 | Pages: 2160-2170

10.1158/0008-5472.can-13-3392 | PMID 24737128 Get It

Abstract The ability to consistently detect cell-free tumor-specific DNA in peripheral blood of patients with metastatic breast cancer provides the opportunity to detect changes in tumor burden and to monitor response to treatment. We developed cMethDNA, a quantitative multiplexed methylation-specific PCR assay for a panel of ten genes, consisting of novel and known breast cancer hypermethylated markers identified by mining our previously reported study of DNA methylation patterns in breast tissue (103 cancer, 21 normal on the Illumina HumanMethylation27 Beadchip) and then validating the 10-gene panel in The Cancer Genome Atlas project breast cancer methylome database. For cMethDNA, a fixed physiologic level (50 copies) of artificially constructed, standard nonhuman reference DNA specific for each gene is introduced in a constant volume of serum (300 μL) before purification of the DNA, facilitating a sensitive, specific, robust, and quantitative assay of tumor DNA, with broad dynamic range. Cancer-specific methylated DNA was detected in training (28 normal, 24 cancer) and test (27 normal, 33 cancer) sets of recurrent stage IV patient sera with a sensitivity of 91% and a specificity of 96% in the test set. In a pilot study, cMethDNA assay faithfully reflected patient response to chemotherapy (N = 29). A core methylation signature present in the primary breast cancer was retained in serum and metastatic tissues collected at autopsy two to 11 years after diagnosis of the disease. Together, our data suggest that the cMethDNA assay can detect advanced breast cancer, and monitor tumor burden and treatment response in women with metastatic breast cancer. Cancer Res; 74(8); 2160–70. ©2014 AACR.